Autonomix Medical (Nasdaq: AMIX) has been granted U.S. Patent No. 12,257,071 for its controlled sympathectomy and micro-ablation systems and methods. The patented technology integrates nerve mapping with radiofrequency (RF) ablation to enable precise, minimally invasive treatment of overactive peripheral nerves.
The Woodlands, Texas-based company’s system features deployable microfingers with embedded sensors that allow real-time nerve monitoring, stimulation, ablation, and assessment—all within a single integrated catheter device. The technology supports feedback-driven control and adaptive modulation, enhancing treatment accuracy for neurological conditions such as chronic pain, hypertension, cardiac modulation, and metabolic disorders.
Autonomix plans to seek FDA investigational device exemption (IDE) approval later this year to initiate U.S. clinical trials.
CEO Brad Hauser stated,
“This patent marks a key milestone in our mission to revolutionize pain management and neurological treatments through minimally invasive methods. It strengthens our IP portfolio and positions us at the forefront of nerve-focused therapeutics.”
Follow MEDWIRE.AI for insights on breakthroughs in neurotherapeutics and catheter-based interventions.
